[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bowel-resection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bowel-resection":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100575765","evaluation-of-rectal-infiltration-depth-and-length-in-bowel-involvement-of-deep-infiltrative-endometriosis-die-using-intraoperative-transrectal-ultrasound-trus-100575765",false,"NCT06776536","Evaluation of Rectal Infiltration Depth and Length in Bowel Involvement of Deep Infiltrative Endometriosis (DIE) Using Intraoperative Transrectal Ultrasound (TRUS)","DIE IO TRUS","Inclusion Criteria:\n\n* The study will include a minimum of 15 female patients aged 18-55 with bowel involvement due to deep infiltrative endometriosis, requiring bowel resection.\n\nExclusion Criteria:\n\nPatients with bowel endometriosis who does not require bowel resection, patients who have other bowel diseases, such as rectal tumors, Crohn's disease, or ulcerative colitis, will be excluded.\n\n\\-","FEMALE","18 Years","55 Years",{"count":20,"type":21},15,"ESTIMATED","INTERVENTIONAL",[24],"NA","we aim to evaluate the success of intraoperative transrectal ultrasound in measuring the depth and extent of bowel involvement in patients preoperatively diagnosed with intestinal endometriosis using transvaginal ultrasound and MRI, and who are planned for bowel resection",[27,28,29,30],"Deep Infiltrating Endometriosis (DIE)","Transrectal Ultrasound","Bowel Endometriosis","Bowel Resection",[32,33,34,35],"Deeply infiltrating endometriosis","bowel endometriosis","transrectal ultrasound","bowel resection","RECRUITING","2025-01-10",{"date":39,"type":40},"2025-01-15","ACTUAL",{"date":42,"type":21},"2025-01-07",{"date":44,"type":21},"2026-04-07",{"name":46,"class":47},"Başakşehir Çam & Sakura City Hospital","OTHER_GOV",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":48},"100526188","segmental-resection-combined-with-dep-regimen-for-ebv-hlh-patients-with-intestinal-involvement-100526188","NCT06131489","Segmental Resection Combined With DEP Regimen for EBV-HLH Patients With Intestinal Involvement","Efficacy and Safety of Segmental Resection Combined With the DEP Regimen for Epstein-Barr Virus Associated Hemophagocytic Lymphohistiocytosis With Intestinal Involvement","Inclusion Criteria:\n\n* Met HLH-2004 diagnostic criteria;\n* EBV-DNA in the peripheral blood \\> 1000 copies\u002Fml or EBV-encoded small RNA (EBER) detected in tissues;\n* Imaging revealed severe intestinal lesions and biopsy confirmed EBV-encoded small RNA (EBER) in the tissues;\n* Age \\>18 years old, gender is not limited;\n* Estimated survival time \\> 1 month;\n* Informed consent obtained.\n\nExclusion Criteria:\n\n* Active infections (viral, bacterial, fungal or parasitic);\n* Diagosed with malignant tumos within 5 years；\n* Uncontrolled symptoms or other diseases including, but not limited to, unstable angina pectoris, arrhythmia, respiratory failure, severe hepatic or renal insufficiency, severe coagulation dysfunction, mental illness, or other conditions deemed by the attending physician to be contraindications to surgery;\n* Heart function above grade II (NYHA);\n* Severe myocardial injury：TNT、TNI、CK-MB \\> 3 ULN;\n* Accumulated dose of doxorubicin above 400mg\u002Fm2 、epirubicin above 750mg\u002Fm2、pirarubicin above 800mg\u002Fm2 or the patients treated with anthracycline induced cardiovascular disease;\n* Pregnancy or lactating Women;\n* Allergic to pegylated liposomal doxorubicin and etoposide;\n* HIV antibody positivity;\n* Acute or chronic active hepatitis B (HBsAg positivity, HBV DNA negative acceptable), acute or chronic active hepatitis C (HCV antibody negatively acceptable; HCV antibody positivity, HCV RNA negative acceptable);\n* Participate in other clinical research at the same time;\n* The researchers considered that patients are not suitable for the study.","ALL",{"count":58,"type":21},20,"OBSERVATIONAL","EBV-HLH is a rare disease with high mortality, especially for those with intestinal involvement. In order to reduce disease burden and improve survival of these patients, we conduct a prospective observational study to explore the efficacy and safety of segmental resection combined with the DEP regimen.",[62,63,30],"Hemophagocytic Lymphohistiocytosis","Epstein-Barr Virus","NOT_YET_RECRUITING","2023-11-09",{"date":67,"type":40},"2023-11-14",{"date":69,"type":21},"2023-12-01",{"date":71,"type":21},"2027-01-01",{"name":73,"class":74},"Beijing Friendship Hospital","OTHER"]